Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Survival is worse among patients with advanced BRAFV600 wild-type melanoma than those with BRAFV600-mutant advanced melanoma during the first 10 months following diagnosis due to limited treatment options, according to a Dutch study.

BRAFV600 wild-type status tied to poorer survival in advanced melanoma

Chronic inflammation tied to lower tumour grade in prostate cancer

Chronic baseline prostate inflammation in a negative biopsy is predictive of a lower prostate cancer grade among men with cancer on follow-up 2-year biopsy, a study has shown.

Chronic inflammation tied to lower tumour grade in prostate cancer

Immune checkpoint inhibitors deliver comparable effectiveness in advanced urothelial carcinoma

The effectiveness of programmed cell death protein 1 or its ligand (L1) inhibitors is similar as regards time to initiation of third therapy or death and overall survival in patients with platinum refractory locally advanced/unresectable or metastatic urothelial carcinoma, a recent study has shown.

Immune checkpoint inhibitors deliver comparable effectiveness in advanced urothelial carcinoma

Pancreatic enzymes supplementation leads to symptomatic recovery in sorafenib-treated HCC

Supplementation with pancreatic enzymes results in symptomatic recovery in hepatocellular carcinoma (HCC), as shown in a study that validated the association between malabsorption (MA) and pancreatic insufficiency (PI) in 10 percent of sorafenib-treated patients.

Pancreatic enzymes supplementation leads to symptomatic recovery in sorafenib-treated HCC

Adjuvant S-1 + docetaxel yields survival benefit for stage III gastric cancer patients following resection

26 Feb 2021 bởi

A combination therapy of S-1 plus docetaxel in the adjuvant setting is not only superior to S-1 alone for recurrence-free survival (RFS) following D2 gastrectomy for stage III gastric cancer, it also confers overall survival (OS) benefit, according to the updated analysis of the JACCRO GC-07 trial presented at ASCO GICS 2021.

Adjuvant S-1 + docetaxel yields survival benefit for stage III gastric cancer patients following resection

Statins yield cancer survival gains in NAFLD patients

Among patients with nonalcoholic fatty liver disease (NAFLD), use of statins considerably reduces cancer-related mortality, a study has found.

Statins yield cancer survival gains in NAFLD patients

Vandetanib beneficial in advanced medullary thyroid cancer

In patients with advanced medullary thyroid cancer, treatment with vandetanib in the first- or second-line setting provides sustained clinical benefit, with predictors of durable response including younger age at diagnosis and absence of progression, according to a study.

Vandetanib beneficial in advanced medullary thyroid cancer

Anthracycline-based chemo poses cardiac hazard in Asian children

25 Feb 2021 bởi

Use of anthracycline class of chemotherapeutic drugs for treating childhood cancer may trigger cardiotoxic effects in a number of children, according to data from a multiethnic Southeast Asian cohort study.

Anthracycline-based chemo poses cardiac hazard in Asian children

Risk of HBV reactivation persists in cancer patients receiving antivirals

Cancer patients administered with prophylactic antiviral drugs are still at risk of hepatitis B virus (HBV) reactivation during chemotherapy, a Taiwan study has found.

Risk of HBV reactivation persists in cancer patients receiving antivirals

PEMBROLIZUMAB PHỐI HỢP HÓA TRỊ, một giải pháp mới cho bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn tiến xa, không đột biến EGFR và ALK – Kể Cả Nhóm Bệnh Nhân Không Bộc Lộ PD-L1: Phân tích theo nghiên cứu KEYNOTE-189, KEYNOTE-407, và phân tích chung (pooled analysis) KEYNOTE-021G, KEYNOTE-189, KEYNOTE-407

Từ tháng 10/2015 cho đến nay, pembrolizumab là thuốc ức chế điểm kiểm soát miễn dịch đã được Cục quản lý Thực phẩm & Dược phẩm Hoa Kỳ (FDA) chấp thuận sử dụng trong điều trị ung thư phổi không tế bào nhỏ (UTPKTBN) giai đoạn tiến xa trong nhiều bối cảnh lâm sàng khác nhau. [FDA Approval Timeline of Active Immunotherapies]

PEMBROLIZUMAB PHỐI HỢP HÓA TRỊ, một giải pháp mới cho bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn tiến xa, không đột biến EGFR và ALK – Kể Cả Nhóm Bệnh Nhân Không Bộc Lộ PD-L1: Phân tích theo nghiên cứu KEYNOTE-189, KEYNOTE-407, và phân tích chung (pooled analysis) KEYNOTE-021G, KEYNOTE-189, KEYNOTE-407